Published in Arch Gen Psychiatry on February 01, 2005
Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study. Neurology (2008) 2.97
Epidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention. Dialogues Clin Neurosci (2009) 2.86
Age-varying association between statin use and incident Alzheimer's disease. J Am Geriatr Soc (2010) 2.34
Vascular risk factors, cognitive decline, and dementia. Vasc Health Risk Manag (2008) 2.13
Statins and cognitive decline in older adults with normal cognition or mild cognitive impairment. J Am Geriatr Soc (2013) 2.11
Effect of statins on a wide range of health outcomes: a cohort study validated by comparison with randomized trials. Br J Clin Pharmacol (2008) 2.03
The Alzheimer's disease beta-secretase enzyme, BACE1. Mol Neurodegener (2007) 1.81
Do statins impair cognition? A systematic review and meta-analysis of randomized controlled trials. J Gen Intern Med (2015) 1.74
Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease. BMC Med (2007) 1.72
Diagnosis and treatment of dementia: 1. Risk assessment and primary prevention of Alzheimer disease. CMAJ (2008) 1.70
Alzheimer disease. Dis Mon (2010) 1.64
Liver X receptor agonist treatment ameliorates amyloid pathology and memory deficits caused by high-fat diet in APP23 mice. J Neurosci (2010) 1.48
Pravastatin and cognitive function in the elderly. Results of the PROSPER study. J Neurol (2009) 1.47
Association of statin use with cognitive decline in elderly African Americans. Neurology (2007) 1.34
Unintended effects of statins from observational studies in the general population: systematic review and meta-analysis. BMC Med (2014) 1.31
Effects of cardiovascular medications on rate of functional decline in Alzheimer disease. Am J Geriatr Psychiatry (2008) 1.27
Promoting successful cognitive aging: a comprehensive review. J Alzheimers Dis (2010) 1.19
Cholesterol level and statin use in Alzheimer disease: II. Review of human trials and recommendations. Arch Neurol (2011) 1.17
Higher serum total cholesterol levels in late middle age are associated with glucose hypometabolism in brain regions affected by Alzheimer's disease and normal aging. Neuroimage (2009) 1.17
Lipid Rafts: Linking Alzheimer's Amyloid-β Production, Aggregation, and Toxicity at Neuronal Membranes. Int J Alzheimers Dis (2010) 1.17
Statins, risk of dementia, and cognitive function: secondary analysis of the ginkgo evaluation of memory study. J Stroke Cerebrovasc Dis (2011) 1.12
Modifiable Midlife Risk Factors for Late-Life Cognitive Impairment and Dementia. Curr Psychiatry Rev (2009) 1.09
The effects of cholesterol on learning and memory. Neurosci Biobehav Rev (2010) 1.05
Increased atherogenic lipoproteins are associated with cognitive impairment: effects of statins and subclinical atherosclerosis. Alzheimer Dis Assoc Disord (2009) 1.02
Adult Changes in Thought study: dementia is an individually varying convergent syndrome with prevalent clinically silent diseases that may be modified by some commonly used therapeutics. Curr Alzheimer Res (2012) 1.01
Potential mechanisms linking cholesterol to Alzheimer's disease-like pathology in rabbit brain, hippocampal organotypic slices, and skeletal muscle. J Alzheimers Dis (2008) 0.97
Cholesterol-related genetic risk scores are associated with hypometabolism in Alzheimer's-affected brain regions. Neuroimage (2008) 0.96
Lipid lowering agents, cognitive decline, and dementia: the three-city study. J Alzheimers Dis (2012) 0.95
Neuropsychiatric consequences of cardiovascular medications. Dialogues Clin Neurosci (2007) 0.92
Ginkgo biloba extract and long-term cognitive decline: a 20-year follow-up population-based study. PLoS One (2013) 0.89
The association of anxiety and depression with future dementia diagnosis: a case-control study in primary care. Fam Pract (2012) 0.89
Interventions for heart disease and their effects on Alzheimer's disease. Neurol Res (2006) 0.87
Use of statins and risk of hospitalization with dementia: a Danish population-based case-control study. Alzheimer Dis Assoc Disord (2009) 0.87
Alzheimer's Disease in Adults with Down Syndrome. Int Rev Res Ment Retard (2008) 0.86
Medications and diet: protective factors for AD? Alzheimer Dis Assoc Disord (2006) 0.85
Statins, cognition, and dementia—systematic review and methodological commentary. Nat Rev Neurol (2015) 0.85
Dyslipidemia and the risk of Alzheimer's disease. Curr Atheroscler Rep (2013) 0.85
Comparison between Complementary Dietary Treatment of Alzheimer Disease in Iranian Traditional Medicine and Modern Medicine. Iran J Public Health (2013) 0.85
Regulation of cerebral cholesterol metabolism in Alzheimer disease. J Investig Med (2012) 0.85
Low-density lipoprotein receptor-related protein 1: a physiological Aβ homeostatic mechanism with multiple therapeutic opportunities. Pharmacol Ther (2012) 0.85
The Cache County Study on Memory in Aging: factors affecting risk of Alzheimer's disease and its progression after onset. Int Rev Psychiatry (2013) 0.84
The prevention and treatment of cognitive decline and dementia: An overview of recent research on experimental treatments. Indian J Psychiatry (2009) 0.84
Effect of pravastatin on plasma sterols and oxysterols in men. Eur J Clin Pharmacol (2005) 0.84
Cardiovascular dementia - a different perspective. Open Biochem J (2010) 0.83
Anti-inflammatory and immune therapy for Alzheimer's disease: current status and future directions. Curr Neuropharmacol (2007) 0.82
Cholesterol level, statin use and Alzheimer's disease in adults with Down syndrome. Neurosci Lett (2007) 0.81
Intracellular cholesterol homeostasis and amyloid precursor protein processing. Biochim Biophys Acta (2010) 0.81
Effects of simvastatin on cholesterol metabolism and Alzheimer disease biomarkers. Alzheimer Dis Assoc Disord (2010) 0.81
Statins more than cholesterol lowering agents in Alzheimer disease: their pleiotropic functions as potential therapeutic targets. Biochem Pharmacol (2013) 0.80
Prevention of Alzheimer's disease in high risk groups: statin therapy in subjects with PSEN1 mutations or heterozygosity for apolipoprotein E epsilon 4. Alzheimers Res Ther (2010) 0.80
Possible modification of Alzheimer's disease by statins in midlife: interactions with genetic and non-genetic risk factors. Front Aging Neurosci (2014) 0.80
Genetic aspects of behavioral neurotoxicology. Neurotoxicology (2009) 0.79
Latest Advances on Interventions that May Prevent, Delay or Ameliorate Dementia. Ther Adv Chronic Dis (2011) 0.79
A review of the potential therapeutic role of statins in the treatment of Alzheimer's disease: current research and opinion. Neuropsychiatr Dis Treat (2013) 0.78
Cholesterol balance in prion diseases and Alzheimer's disease. Viruses (2014) 0.77
Toward onset prevention of cognitive decline in adults with Down syndrome (the TOP-COG study): study protocol for a randomized controlled trial. Trials (2014) 0.77
Sex and Race Differences in the Association Between Statin Use and the Incidence of Alzheimer Disease. JAMA Neurol (2016) 0.77
Therapeutic interventions targeting Beta amyloid pathogenesis in an aging dog model. Curr Neuropharmacol (2011) 0.76
Prevention of dementia: Role of vascular risk factors and cerebral emboli. Indian J Psychiatry (2009) 0.76
Modeling cholesterol metabolism by gene expression profiling in the hippocampus. Mol Biosyst (2011) 0.76
Towards onset prevention of cognition decline in adults with Down syndrome (The TOP-COG study): A pilot randomised controlled trial. Trials (2016) 0.75
The relationship of cardiovascular risk factors to Alzheimer disease in Choctaw Indians. Am J Geriatr Psychiatry (2011) 0.75
Commentary on "the Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): design and baseline characteristics". Alzheimers Dement (2008) 0.75
Statins and therapy of Alzheimer's disease: questions of efficacy versus trial design. Alzheimers Res Ther (2012) 0.75
A roadmap for the prevention of dementia II: Leon Thal Symposium 2008. Alzheimers Dement (2009) 10.21
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet (2011) 10.07
Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med (2007) 6.80
Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study. JAMA (2002) 6.72
A roadmap for the prevention of dementia: the inaugural Leon Thal Symposium. Alzheimers Dement (2008) 6.39
Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet (2010) 5.52
Tissue-specific genetic control of splicing: implications for the study of complex traits. PLoS Biol (2008) 5.08
Developing a national strategy to prevent dementia: Leon Thal Symposium 2009. Alzheimers Dement (2010) 4.85
Incidence and prevalence of dementia in the Cardiovascular Health Study. J Am Geriatr Soc (2004) 3.43
Treatment course with antidepressant therapy in late-life depression. Am J Psychiatry (2012) 2.94
Age at onset in two common neurodegenerative diseases is genetically controlled. Am J Hum Genet (2002) 2.90
Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. Arch Neurol (2008) 2.86
Antihypertensive medication use and incident Alzheimer disease: the Cache County Study. Arch Neurol (2006) 2.71
Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer's disease: a systematic review. Neuroepidemiology (2004) 2.63
Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the Cache County Study. Arch Neurol (2004) 2.62
Comparison of clinical and neuropathologic diagnoses of Alzheimer's disease in 3 epidemiologic samples. Alzheimers Dement (2006) 2.51
Analysis of European mitochondrial haplogroups with Alzheimer disease risk. Neurosci Lett (2004) 2.36
Age-varying association between statin use and incident Alzheimer's disease. J Am Geriatr Soc (2010) 2.34
Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study. Int J Geriatr Psychiatry (2008) 2.32
Metabolomics in early Alzheimer's disease: identification of altered plasma sphingolipidome using shotgun lipidomics. PLoS One (2011) 2.30
Perspectives on depression, mild cognitive impairment, and cognitive decline. Arch Gen Psychiatry (2006) 2.29
Central nervous system injury associated with cardiac surgery. Lancet (2006) 2.27
Reduced incidence of AD with NSAID but not H2 receptor antagonists: the Cache County Study. Neurology (2002) 2.12
Novel late-onset Alzheimer disease loci variants associate with brain gene expression. Neurology (2012) 2.08
Effects of the dietary approaches to stop hypertension diet, exercise, and caloric restriction on neurocognition in overweight adults with high blood pressure. Hypertension (2010) 2.07
Glutathione S-transferase omega-1 modifies age-at-onset of Alzheimer disease and Parkinson disease. Hum Mol Genet (2003) 1.98
Head injury in early adulthood and the lifetime risk of depression. Arch Gen Psychiatry (2002) 1.97
Hormone therapy and Alzheimer disease dementia: new findings from the Cache County Study. Neurology (2012) 1.96
Consortium to Establish a Registry for Alzheimer's Disease (CERAD): the first twenty years. Alzheimers Dement (2008) 1.90
An adaptation of the modified mini-mental state examination: analysis of demographic influences and normative data: the cache county study. Neuropsychiatry Neuropsychol Behav Neurol (2002) 1.89
Vascular risk factors for incident Alzheimer disease and vascular dementia: the Cache County study. Alzheimer Dis Assoc Disord (2006) 1.85
Progression of cognitive, functional, and neuropsychiatric symptom domains in a population cohort with Alzheimer dementia: the Cache County Dementia Progression study. Am J Geriatr Psychiatry (2011) 1.83
Neuropsychiatric symptoms in Alzheimer's disease. Alzheimers Dement (2011) 1.81
Enriched white matter connectivity networks for accurate identification of MCI patients. Neuroimage (2010) 1.79
Dystrophic microglia in the aging human brain. Glia (2004) 1.79
Identification of MCI individuals using structural and functional connectivity networks. Neuroimage (2011) 1.77
Relationship of cognitive measures and gray and white matter in Alzheimer's disease. J Alzheimers Dis (2006) 1.74
Greater risk of dementia when spouse has dementia? The Cache County study. J Am Geriatr Soc (2010) 1.73
Free radical damage to cerebral cortex in Alzheimer's disease, microvascular brain injury, and smoking. Ann Neurol (2009) 1.71
Methodology and preliminary results from the neurocognitive outcomes of depression in the elderly study. J Geriatr Psychiatry Neurol (2004) 1.69
Apolipoprotein E epsilon4 count affects age at onset of Alzheimer disease, but not lifetime susceptibility: The Cache County Study. Arch Gen Psychiatry (2004) 1.67
Neuropsychiatric symptoms as predictors of progression to severe Alzheimer's dementia and death: the Cache County Dementia Progression Study. Am J Psychiatry (2015) 1.65
Incidence of dementia and cognitive impairment, not dementia in the United States. Ann Neurol (2011) 1.63
Effects of family history and apolipoprotein E epsilon4 status on cognitive decline in the absence of Alzheimer dementia: the Cache County Study. Arch Neurol (2009) 1.63
Temporal lobe functional activity and connectivity in young adult APOE varepsilon4 carriers. Alzheimers Dement (2009) 1.60
White matter lesions, quantitative magnetic resonance imaging, and dementia. Alzheimer Dis Assoc Disord (2002) 1.59
Treating depression in Alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS. Arch Gen Psychiatry (2003) 1.50
Epidemiology of apathy in older adults: the Cache County Study. Am J Geriatr Psychiatry (2007) 1.50
The persistence of neuropsychiatric symptoms in dementia: the Cache County Study. Int J Geriatr Psychiatry (2004) 1.46
Persistent mild cognitive impairment in geriatric depression. Int Psychogeriatr (2006) 1.45
Antioxidant vitamin supplement use and risk of dementia or Alzheimer's disease in older adults. J Am Geriatr Soc (2007) 1.44
Can we prevent Alzheimer's disease? Secondary "prevention" trials in Alzheimer's disease. Alzheimers Dement (2013) 1.38
Genome-wide scan of copy number variation in late-onset Alzheimer's disease. J Alzheimers Dis (2010) 1.35
Ordered-subsets linkage analysis detects novel Alzheimer disease loci on chromosomes 2q34 and 15q22. Am J Hum Genet (2003) 1.35
Longitudinal magnetic resonance imaging vascular changes, apolipoprotein E genotype, and development of dementia in the neurocognitive outcomes of depression in the elderly study. Am J Geriatr Psychiatry (2007) 1.35
Genetic regulation of alpha-synuclein mRNA expression in various human brain tissues. PLoS One (2009) 1.34
Caregiver-recipient closeness and symptom progression in Alzheimer disease. The Cache County Dementia Progression Study. J Gerontol B Psychol Sci Soc Sci (2009) 1.33
Double placebo design in a prevention trial for Alzheimer's disease. Control Clin Trials (2002) 1.30
Alzheimer's Disease Anti-inflammatory Prevention Trial: design, methods, and baseline results. Alzheimers Dement (2009) 1.28
Operationalizing diagnostic criteria for Alzheimer's disease and other age-related cognitive impairment-Part 1. Alzheimers Dement (2011) 1.26
Biomarkers for cognitive impairment and dementia in elderly people. Lancet Neurol (2008) 1.25
Population-based study of medical comorbidity in early dementia and "cognitive impairment, no dementia (CIND)": association with functional and cognitive impairment: The Cache County Study. Am J Geriatr Psychiatry (2005) 1.23
Hippocampal volume and incident dementia in geriatric depression. Am J Geriatr Psychiatry (2002) 1.22
Microglial dystrophy in the aged and Alzheimer's disease brain is associated with ferritin immunoreactivity. Glia (2008) 1.21
Duke Twins Study of Memory in Aging in the NAS-NRC Twin Registry. Twin Res Hum Genet (2006) 1.19
Factor structure of the National Alzheimer's Coordinating Centers uniform dataset neuropsychological battery: an evaluation of invariance between and within groups over time. Alzheimer Dis Assoc Disord (2011) 1.19
The incidence of mental and behavioral disturbances in dementia: the cache county study. J Neuropsychiatry Clin Neurosci (2003) 1.18
Atrial fibrillation and risk of dementia: a prospective cohort study. J Am Geriatr Soc (2011) 1.18
Age-varying association between blood pressure and risk of dementia in those aged 65 and older: a community-based prospective cohort study. J Am Geriatr Soc (2007) 1.16
Alzheimer disease pathology in cognitively healthy elderly: a genome-wide study. Neurobiol Aging (2010) 1.16
Effects of non-steroidal anti-inflammatory drug treatments on cognitive decline vary by phase of pre-clinical Alzheimer disease: findings from the randomized controlled Alzheimer's Disease Anti-inflammatory Prevention Trial. Int J Geriatr Psychiatry (2011) 1.16
Neurocognitive correlates of response to treatment in late-life depression. Am J Geriatr Psychiatry (2008) 1.15
Characteristics of a two-stage screen for incident dementia. J Clin Epidemiol (2003) 1.13
Ten dimensions of health and their relationships with overall self-reported health and survival in a predominately religiously active elderly population: the cache county memory study. J Am Geriatr Soc (2006) 1.11
Prospective study of Dietary Approaches to Stop Hypertension- and Mediterranean-style dietary patterns and age-related cognitive change: the Cache County Study on Memory, Health and Aging. Am J Clin Nutr (2013) 1.11